Colin Sandercock - 09 Feb 2022 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
SVP, GENERAL COUNSEL
Signature
/s/ Colin Sandercock
Issuer symbol
CUE
Transactions as of
09 Feb 2022
Transactions value $
$0
Form type
4
Date filed
29 Mar 2022, 16:13
Next filing
21 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +60K $0.00 60K 09 Feb 2022 Common Stock 60K $6.91 Direct F1
transaction CUE Stock Option (right to buy) Award $0 +16.7K $0.00 16.7K 25 Mar 2022 Common Stock 16.7K $5.01 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1. This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 9, 2022.
F2 2. This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 25, 2022.